- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Jeffrey S. Bucholtz
Insight 29 results
Client Alert
July 30, 2020
Trump Administration Continues to Promote Drug Importation as a Way to Lower the Cost of Prescription Drugs
Article · Source: Chamber Litigation Blog
June 10, 2020
The Nuisance of Nuisance Litigation
Client Alert
April 28, 2020
Constitutional Limitations On Emergency Authority
Client Alert
April 9, 2020
False Claims Act Considerations Related to the CARES Act's Small Business Administration Loan Program
Article · Source: Law360
March 19, 2020
Ruling In HHS Case May Mean More Drug Trial Reporting
Client Alert
Article · Source: Washington Legal Foundation
December 13, 2019
Taking the Granston Memo to the Next Level: Early and Close Coordination with Agencies on Qui Tam Actions
Client Alert
October 15, 2019
Taking Cues from Justice Department, New Executive Orders Limit Agency Use of Guidance to Establish and Enforce Regulatory Policy
Client Alert
September 24, 2018
Echoes of the Brand Memo
Client Alert
January 31, 2018
The Brand Memorandum: DOJ Restricts Reliance on Agency Guidance in Civil Enforcement Actions
Client Alert
January 26, 2017
FDA Defends Its First Amendment Position in “Memorandum”
Client Alert
January 19, 2017
FDA Takes Action in the Last Days of the Obama Administration to Clarify Some of Its Views on Off-Label Communications